What are resistance rates to fluoroquinolones in the treatment of chronic bacterial prostatitis (CBP)?

Updated: May 25, 2021
  • Author: Samantha D Kraemer, MD; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print

Fluoroquinolone therapy is not always feasible in patients with contraindications such as long QT syndrome or tendonitis. Reported resistance rates to fluoroquinolones in Enterobacteriaceae causing urinary tract or intra-abdominal infections have increased in previous years and exceed 50% in some parts of the world, especially Asia. In Europe and North America, resistance rates range from less than 10% in rural areas to more than 30% in sexual networks. [44]

National and international antibiotic stewardship practices have helped to lower the percentage of ciprofloxacin-resistant extended-spectrum β-lactamase (ESBL) Enterobacteriaceae in urinary isolates in both hospital and community settings. [45] Nevertheless, alternative antibiotics for treating CBP are needed.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!